Janssen News Releases
Janssen News Releases
3 FOLLOWERS
At Janssen, we never stop working toward a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Explore our news, updates, research..
Findings Presented at ACC.24 Showed XARELTO® (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
Janssen News Releases
by
1w ago
..read more
Visit website
Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology’s 2024 Annual Meeting
Janssen News Releases
by
1w ago
..read more
Visit website
Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24
Janssen News Releases
by
2w ago
..read more
Visit website
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Janssen News Releases
by
2w ago
..read more
Visit website
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Janssen News Releases
by
1M ago
..read more
Visit website
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
Janssen News Releases
by
1M ago
..read more
Visit website
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
Janssen News Releases
by
1M ago
..read more
Visit website
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
Janssen News Releases
by
1M ago
..read more
Visit website
Johnson & Johnson Completes Acquisition of Ambrx
Janssen News Releases
by
1M ago
..read more
Visit website
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
Janssen News Releases
by
1M ago
..read more
Visit website

Follow Janssen News Releases on FeedSpot

Continue with Google
Continue with Apple
OR